Beovu Archives -

FDA clears Roche’s Susvimo implant for eye disease wet AMD

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis, ophthalmology, Regeneron, Roche, Susvimo, wet AMD 0 Comment

Roche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration

FDA clears Roche’s Susvimo implant for eye disease wet AMD

https://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/

News/ News/ Sales and Marketing

Novartis says trials back Beovu safety in diabetic eye disease

Phil Taylor Bayer, Beovu, diabetic macular oedema, Eylea, Lucentis, Novartis, ophthalmology, Regeneron 0 Comment

There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to

Novartis says trials back Beovu safety in diabetic eye disease

https://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/

Market Access/ News/ News

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

Phil Taylor age-related macular degeneration, Bayer, Beovu, diabetic macular oedema, diabetic retinopathy, Eylea, faricimab, Novartis, ophthalmology, Regeneron, Roche 0 Comment

The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness,

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

https://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/

Market Access/ News/ News

Roche eyes October decision by FDA for wet AMD implant

Phil Taylor age-related macular degeneration, Beovu, Eylea, fda, Lucentis, Novartis, ophthalmology, Regeneron, Roche, wet AMD 0 Comment

The FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related

Roche eyes October decision by FDA for wet AMD implant

https://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/

Market Access/ News/ News

UK patient group warns COVID could limit access to Novartis’ new eye drug

Richard Staines Bayer, Beovu, market access, NICE, Novartis, ophthalmology, Regeneron 0 Comment

NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales –

UK patient group warns COVID could limit access to Novartis’ new eye drug

https://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/

MyTherapy Novartis - See What's Next (002)

Digital/ News/ News

Novartis taps smartpatient for app to support wet AMD patients

Phil Taylor app, Beovu, digital, digital health, Lucentis, Novartis, ophthalmology, smartpatient, wet AMD 0 Comment

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet

Novartis taps smartpatient for app to support wet AMD patients

https://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/

News/ Top stories

Novartis’ Beovu safety woes could cost billions of dollars, says analyst

Richard Staines Bayer, Beovu, Novartis, ophthalmology, Regeneron, safety, wet AMD 0 Comment

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several

Novartis’ Beovu safety woes could cost billions of dollars, says analyst

https://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/

Market Access/ News/ News

Novartis’ blockbuster hope Beovu clears EMA advisory panel

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis 0 Comment

Novartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green

Novartis’ blockbuster hope Beovu clears EMA advisory panel

https://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/

Trending

Beovu

Login